Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $12.67.

Several analysts have issued reports on the company. Wall Street Zen upgraded Verrica Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Finally, Lake Street Capital started coverage on Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective for the company.

Get Verrica Pharmaceuticals alerts:

View Our Latest Analysis on Verrica Pharmaceuticals

Verrica Pharmaceuticals Stock Down 10.7%

Verrica Pharmaceuticals stock opened at $3.58 on Friday. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The firm has a 50 day moving average price of $4.80 and a 200-day moving average price of $5.58. The company has a market capitalization of $61.50 million, a P/E ratio of -2.14 and a beta of 1.60. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Renaissance Technologies LLC raised its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) by 22.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,360 shares of the company’s stock after acquiring an additional 5,960 shares during the period. Renaissance Technologies LLC owned approximately 0.19% of Verrica Pharmaceuticals worth $171,000 at the end of the most recent reporting period. Institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases with limited or inadequate therapeutic options. The company’s work centers on topical therapies designed for use in dermatology practices and other healthcare settings.

Verrica’s lead product, YCANTHE (cantharidin), is a topical solution approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children two years of age and older.

Featured Stories

• Five stocks we like better than Verrica Pharmaceuticals
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.